Stouffville Eyes Possible Hotel on Clippers Arena Parking Lot
● Stouffville is proposing a zoning change for municipally owned land at 100, 110, and 120 Weldon Road.
● The site includes the Clippers Sports Complex, Fire Station 5-1, a new daycare, and surplus parking spaces.
● A hotel developer has expressed interest in building on the eastern end of the lot.
● The land is already designated for hotel uses under the new Official Plan, but requires rezoning.
● Mayor Iain Lovatt said a hotel would keep tourism dollars in town and support economic growth.
● Public consultation will be part of the planning process if development proceeds.
A patch of municipal land on Weldon Road, currently occupied by parking spaces, could soon be home to a new hotel.
The Town is proposing a zoning change for its properties at 100, 110, and 120 Weldon Rd., which include Fire Station 5-1, the Clippers Sports Complex, a
modular daycare facility
under construction, and a large surface parking lot. Officials say the eastern portion of that lot may soon serve a new purpose.
'There is somebody who wants to put a hotel...on the east end of the parking lot, which is actually a pretty interesting idea because we have 126 more spots than is required for the arena,' Mayor Iain Lovatt said during an April 23 town hall meeting at Latcham Hall.
In Stouffville, arenas must provide two parking spaces for every 100 square metres of sports fields or rink space. For the Clippers Sports Complex, that translates to a requirement of 143 spaces. Excluding those designated for Fire Station 5-1, the adjacent surface lot contains 269 parking spaces.
'This is a conversation that we are having with the proponent, who is a seasoned hotel operator,' Lovatt noted. The stated interest from the hospitality sector was also included in a related
Staff report
coming to a Public Planning Meeting on Wednesday, May 7.
The site falls within the Western Approach Mixed-Use area of Stouffville's new and in-force Official Plans, which already permit hotel uses. This means no Official Plan Amendment would be required for the project to proceed.
However, the property is currently zoned 'Institutional' under the Town's Comprehensive Zoning By-law, which prohibits hotel uses. Town Staff are recommending the zoning be changed to 'Commercial Mixed Use – Western Approach' (CM2), a designation that would accommodate a hotel and align with the broader land-use permissions laid out in the Official Plan.
In addition to hotel uses, the CM2 zoning would also allow for residential development such as condominiums or apartment buildings.
'The proposed CM2 zone permits a maximum height of 20 metres. This is approximately six storeys, depending on the architectural style of the building,' Staff explained to Bullet Point News. 'The total number of rooms will be dependent on the amount of parking that is able to be accommodated and the specifications of the eventual hotelier. It has been indicated that the site could accommodate a 70-100 room product.'
'We need a hotel in our community,' Lovatt said. 'We have families that come here who have kids that play hockey, for example, and they go stay in Markham and spend all of their money there. We're missing out on that, and we're seeing money leave our community.'
Beyond addressing a local shortage of hotel rooms, the project would bolster Stouffville's economic tax base. Hotels are considered employment-generating uses, which means they are subject to commercial property taxes. Lovatt also pointed out that guests would pay an additional Value Added Tax (VAT), contributing further to the municipality.
Stouffville's Economic Development team has been working with a hotelier to find a viable location for some time. An earlier investigation considered land near Highway 48 and Hoover Park Drive, but the site proved unfeasible.
'All we're doing at this point is looking at changing the zoning in the eastern part of the parking lot to allow this to happen,' Lovatt explained. 'I'm not saying that it is going to happen, but it gives us the flexibility.'
Any future development would still need to go through the formal planning process, which includes public consultation.
'People can come and speak about the application during a Public Planning Meeting and whether that is a good use of those parking spaces just south of the Fire Hall,' Lovatt added.
The May 7 Public Planning Meeting presenting the rezoning proposal will take place in Council Chambers at 7 p.m. Whether or not the hotel is ultimately built, the zoning change would represent a strategic shift that could turn underutilized asphalt into an economic anchor for the community.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
The LGL Group, Inc. Adds Over-Subscription Privilege to Outstanding Warrants, Files Post-Effective Amendment to the Related Registration Statement
Orlando, Florida--(Newsfile Corp. - June 5, 2025) - The LGL Group, Inc. (NYSE American: LGL) (NYSE American: LGL WS) ("LGL Group" or the "Company") today announced that is has added an Over-Subscription Privilege to its outstanding warrants to purchase common stock which were originally issued as a dividend to LGL Group stockholders on November 16, 2020 (the "Warrants"). The Company will file with the Securities and Exchange Commission (the "SEC") a post-effective amendment to its related registration statement on Form S-1 that, once declared effective, will permit holders to exercise the Warrants up and until to their expiration at the close of business on November 16, 2025, a Sunday, which allows holders to exercise the Warrants by the close of business on November 17, 2025 (the "Expiration Date"). Current Exercise Price of Warrants As a result of the previously announced downward adjustment of the exercise price triggered by the spinoff of M-tron Industries, Inc., five (5) Warrants are exercisable to purchase one share of common stock at an exercise price of $4.75. Addition of Over-Subscription Privilege The Company has amended the warrant agreement to add an Over-Subscription Privilege that will from and after close of business on October 16, 2025 (the "Over-Subscription Commencement Date") until the Expiration Date allow warrant holders to subscribe for additional shares of common stock that remain unsubscribed as a result of any unexercised Warrants. The total number of shares of common stock that will be available to all holders who exercise their Warrants and elect the Over-Subscription Privilege will be the number of shares which are not subscribed for as of the Expiration Date pursuant to the basic warrant exercise rights of all holders. Holders that exercise the Warrants prior to the Over-Subscription Commencement Date will not be entitled to subscribe for additional shares pursuant to the Over-Subscription Privilege. Further information concerning how to exercise LGL Group Warrants can be found on the Warrant FAQ page of the Company's website at None of the Company, its board of directors or employees has made or is making any representation or recommendation to any holder of the Warrants as to whether to exercise or refrain from exercising any Warrants. Pending Registration LGL Group will file with the SEC a post-effective registration statement on Form S-1 (No. 333-158319) that includes a prospectus relating to the offering of the shares of common stock issuable upon exercise of the Warrants. The securities being registered may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. Copies of the prospectus for the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at Warrant Agent Computershare Inc. and its wholly-owned subsidiary, Computershare Trust Company, N.A. (together "Computershare"), serve as the Company's warrant agent. All holders of LGL Group's warrants should direct all questions concerning the Warrants to Computershare at: By telephone (within the U.S., U.S. territories and Canada): 1-800-546-5141 By telephone (outside the U.S., U.S. territories and Canada): 1-781-575-2765 If delivering by U.S. mail: Computershare Trust Company, N.A.c/o Voluntary Corporate ActionsP.O. Box 43011Providence, RI 02940-3011 If delivering by courier: Computershare Trust Company, N.A.c/o Voluntary Corporate Actions150 Royall Street, Suite VCanton, MA 02021 The warrant FAQs relating to their original issuance and amendments made to date can be found: About The LGL Group, Inc. The LGL Group, Inc. ("LGL," "LGL Group," or the "Company") is a holding company engaged in services, merchant investment and manufacturing business activities. Precise Time and Frequency, LLC ("PTF") is a globally positioned producer of industrial Electronic Instruments and commercial products and services. Founded in 2002, PTF operates from our design and manufacturing facility in Wakefield, Massachusetts. Lynch Capital International LLC is focused on the development of value through investments. LGL Group was incorporated in 1928 under the laws of the State of Indiana, and in 2007, the Company was reincorporated under the laws of the State of Delaware as The LGL Group, Inc. We maintain our executive offices at 2525 Shader Road, Orlando, Florida 32804. Our telephone number is (407) 298-2000. Our Internet address is LGL Group common stock and warrants are traded on the NYSE American under the symbols "LGL" and "LGL WS," respectively. LGL Group's business strategy is primarily focused on growth through expanding new and existing operations across diversified industries. The Company's engineering and design origins date back to the early 1900s. In 1917, Lynch Glass Machinery Company ("Lynch Glass"), the predecessor of LGL Group, was formed and emerged in the late 1920s as a successful manufacturer of glass-forming machinery. Lynch Glass was then renamed Lynch Corporation ("Lynch") and was incorporated in 1928 under the laws of the State of Indiana. In 1946, Lynch was listed on the "New York Curb Exchange," the predecessor to the NYSE American. The Company has a had a long history of owning and operating various business in the precision engineering, manufacturing, and services sectors. Cautionary Note Concerning Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as those pertaining to the Company's financial condition, results of operations, business strategy and financial needs. All statements other than statements of current or historical fact contained in this press release are forward-looking statements. The words "believe," "expect," "anticipate," "should," "plan," "will," "may," "could," "intend," "estimate," "predict," "potential," "continue" or the negative of these terms and similar expressions, as they relate to LGL Group, are intended to identify forward-looking statements. These forward-looking statements are largely based on current expectations and projections about future events and financial trends that may affect the financial condition, results of operations, business strategy and financial needs of the Company. They can be affected by inaccurate assumptions, including the risks, uncertainties and assumptions described in the filings made by LGL Group with the Securities and Exchange Commission ("SEC"), including those risks set forth under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025. In light of these risks, uncertainties and assumptions, the forward-looking statements in this press release may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements. When you consider these forward-looking statements, you should keep in mind these risk factors and other cautionary statements in this press release. These forward-looking statements speak only as of the date of this press release. LGL Group undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. No Offer or Solicitation This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy common stock of the Company or any other securities and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. ### Contact: The LGL Group, To view the source version of this press release, please visit
Yahoo
5 hours ago
- Yahoo
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial
Estrella Immunopharma, Inc. (NASDAQ:ESLA) has announced a major milestone in its STARLIGHT-1 Phase I/II clinical trial, dosing the first patient in the second cohort of its dose escalation study for EB103. EB103 is an innovative CD19-redirected ARTEMIS T-cell therapy designed to treat advanced B-cell Non-Hodgkin's Lymphomas (NHL). This next phase follows a successful first cohort, which reported no dose-limiting toxicities or serious adverse events, and even saw a complete response in one patient. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. The second cohort will test EB103 at a higher dose, aiming to further establish safety and efficacy. Estrella Immunopharma, Inc. (NASDAQ:ESLA)'s CEO, Cheng Liu, highlighted the therapy's potential to overcome limitations of conventional CAR-T treatments, particularly for high-risk groups such as patients with HIV-associated or CNS lymphomas, populations often excluded from current therapies. EB103 leverages proprietary ARTEMIS technology, allowing T-cells to more precisely target and destroy cancer cells. Estrella Immunopharma, Inc. (NASDAQ:ESLA)'s pipeline also includes EB104, targeting both CD19 and CD22 proteins found in most B-cell malignancies. The company's progress signals hope for broader, safer, and more effective immunotherapies for cancer and autoimmune disease patients. While we acknowledge the potential of ESLA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ESLA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Indianapolis Star
5 hours ago
- Indianapolis Star
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival – highlighting Telomir-1's potential to reverse key hallmarks of aging MIAMI, FL / ACCESS Newswire Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the 'Company,' an emerging leader in age-reversal science, today announced compelling new preclinical data demonstrating that its lead candidate, Telomir-1, administered orally, significantly increases telomere length, reverses body weight and muscle loss, and resets cellular aging markers in a validated animal model of Werner Syndrome (WS) -a rare genetic disorder also known as adult-onset progeria. These findings confirm and build upon the Company's previously reported results from a preclinical C. elegans study, which demonstrated that Telomir-1 restored lifespan and normalized physiological decline in animals with a wrn gene mutation. Werner Syndrome: A Rare and Devastating Accelerated Aging Disorder Werner Syndrome is a rare autosomal recessive disorder caused by mutations in the wrn gene, which plays a critical role in DNA repair and telomere maintenance. Patients typically begin showing signs of premature aging-such as graying hair, cataracts, diabetes, osteoporosis, and atherosclerosis-in their 20s or 30s. Median life expectancy is 40-50 years. There are currently no FDA-approved treatments. To model this disease, the Company's study utilized the Sen57wrn-/-ND6-/+ zebrafish model, which replicates key features of Werner Syndrome, including telomere loss, mitochondrial dysfunction, retinal degeneration, muscle deterioration, and abnormal DNA methylation. Key Preclinical Findings 1. DNA Methylation Reversal – Resetting the Genetic Clock DNA methylation is one of the body's key mechanisms for controlling which genes are turned on or off. It works by attaching small chemical tags (called methyl groups) to DNA at locations known as CpG islands -which act like gene 'on/off' switches. When methylation patterns are intact, cells know which genes to express and when. However, with aging and disease, this regulatory system starts to break down – a phenomenon known as epigenetic drift. In these cases, genes that should be off may turn on inappropriately, and protective genes may be silenced. This malfunction in gene regulation is strongly linked to a wide range of chronic diseases including: Cancer (via silencing of tumor suppressor genes) Neurodegenerative diseases like Alzheimer's and Parkinson's Autoimmune diseases such as lupus and multiple sclerosis Metabolic conditions like Type 2 diabetes Premature aging disorders like progeria and Werner Syndrome In this study, Telomir-1 reversed age-related hypomethylation at two chromosomal regions, restoring methylation patterns to above-normal wild-type levels. This suggests that Telomir-1 may help restore healthy gene regulation and reset the body's epigenetic aging clock, reducing the risk of dysfunction in key biological systems. 2. Telomere Elongation – Rebuilding the Chromosomal Clock Telomeres are the protective caps at the ends of chromosomes that shorten with each cell division and under stress. Telomere shortening is considered one of the hallmarks of aging. In the study, compared with the shortened length in the mutated animals, Telomir-1 increased telomere length by about three-fold. At the higher dose, telomere length significantly exceeded wild-type (healthy) levels, suggesting not only restoration but also potential enhancement of chromosomal integrity 3. Muscle Mass and Body Weight Recovery In the wrn-mutant zebrafish model, animals exhibited a 50-60% reduction in body weight and muscle volume. After 14 days of Telomir-1 treatment, these physical markers were restored to levels statistically indistinguishable from healthy controls – indicating functional recovery and metabolic improvement. 4. Oxidative Stress Reduction Reactive oxygen species (ROS), which damage cells and accelerate aging, were elevated in untreated animals. Telomir-1 reduced ROS levels by up to 50%, suggesting improved cellular resilience. 5. Survival Benefit Roughly 15% of untreated animals died during the 14-day study period, whereas no deaths occurred in any Telomir-1 treated groups – highlighting a systemic survival advantage. 'These results reinforce my conviction that Telomir-1 may represent one of the most important scientific developments in the field of aging,' said Erez Aminov, Chairman and CEO of Telomir. 'While we remain in the preclinical phase, the consistency and strength of the data demand serious attention. My full commitment is behind advancing Telomir-1 toward human studies in the most responsible and rigorous way. The potential here is too significant to ignore.' 'This is one of the most comprehensive rejuvenation profiles we've seen in a vertebrate aging model,' added Dr. Itzchak Angel, Chief Scientific Advisor. 'The ability to reverse both genomic and epigenetic instability while improving survival supports the growing potential of Telomir-1 as a foundational therapy for aging-related diseases.' Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information SOURCE: Telomir Pharmaceuticals, Inc View the original press release on ACCESS Newswire
